Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD044
MIFTS: 55

Bladder Disease

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Disease

About this section

MalaCards integrated aliases for Bladder Disease:

Name: Bladder Disease 38 12 15
Urinary Bladder Diseases 44 73
Bladder Diseases 55 43
Urinary Bladder Disease 12

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:365
ICD9CM 35 596.9
MeSH 44 D001745
NCIt 50 C2900
UMLS 73 C0005686
Sources

Summaries for Bladder Disease

About this section
MedlinePlus : 43 The bladder is a hollow organ in your lower abdomen that stores urine. Many conditions can affect your bladder. Some common ones are Cystitis - inflammation of the bladder, often from an infection Urinary incontinence - loss of bladder control Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination Bladder cancer Doctors diagnose bladder diseases using different tests. These include urine tests, x-rays, and an examination of the bladder wall with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bladder Disease, also known as urinary bladder diseases, is related to interstitial cystitis and cystitis, and has symptoms including bladder fullness sensation An important gene associated with Bladder Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Calcium signaling pathway and Overview of nanoparticle effects. The drugs Hyaluronic acid and Mirabegron have been mentioned in the context of this disorder. Affiliated tissues include the bladder, prostate and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A urinary system disease that is located in the bladder.

Wikipedia : 76 Urinary bladder disease includes urinary bladder inflammation such as cystitis, bladder rupture and... more...

Sources

Related Diseases for Bladder Disease

About this section

Diseases related to Bladder Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 interstitial cystitis 28.1 HBEGF IL6 NGF P2RX3 TAC1 TRPV1
2 cystitis 26.6 CRP HBEGF IL6 NGF P2RX3 TAC1
3 ureterolithiasis 10.9 CHRM3 TRPV1
4 neuroschistosomiasis 10.8 NGF TAC1
5 lesion of sciatic nerve 10.8 NGF TRPV1
6 gallbladder disease 10.8
7 prurigo nodularis 10.8 NGF TAC1
8 cold agglutinin disease 10.7 CRP IL6
9 splenic abscess 10.7 CRP IER3IP1
10 somatoform disorder 10.7 NGF TAC1 TRPV1
11 chronic cystitis 10.6 NGF PPIG UPK3A
12 cough variant asthma 10.6 NGF TRPV1
13 ischemic neuropathy 10.6 CRP NGF
14 diphyllobothriasis 10.6
15 pain agnosia 10.6 IER3IP1 TAC1 TRPV1
16 agnosia 10.6 IER3IP1 TAC1 TRPV1
17 cryopyrin-associated periodic syndrome 10.6 CRP IL6
18 bronchial disease 10.6 IER3IP1 TAC1 TRPV1
19 cardiogenic shock 10.6 CRP IL6
20 perinatal necrotizing enterocolitis 10.6 CRP HBEGF IL6
21 acute cholangitis 10.5 CRP IL6
22 acute maxillary sinusitis 10.5 CRP PPIG
23 pancreas disease 10.5 CRP IL6 TRPV1
24 neutrophilia, hereditary 10.5 CRP IL6
25 rosacea 10.5 IER3IP1 IL6 TRPV1
26 specific developmental disorder 10.5 IER3IP1 TAC1 TRPV1
27 urethral calculus 10.5 KLK3 MCU
28 primary bacterial infectious disease 10.5 CRP HBEGF IL6
29 bone inflammation disease 10.5 CRP IL6 TRPV1
30 chlamydia 10.5 CRP IDO1 IL6
31 mouth disease 10.5 CRP IL6 TRPV1
32 overnutrition 10.5 CRP IL6 TRPV1
33 arteries, anomalies of 10.5 CRP IL6 TRPV1
34 immune system disease 10.5 CRP IL6 TRPV1
35 paine syndrome 10.4 NGF TAC1 TRPV1 UPK3A
36 reproductive system disease 10.4 IL6 KLK3 TRPV1
37 gastrointestinal system disease 10.4 CRP IL6 TRPV1
38 radiation cystitis 10.4 KLK3 NME1-NME2 UPK3A
39 uremic pruritus 10.4 CRP IL6
40 urethral diverticulum 10.3 KLK3 MCU UPK3A
41 pulmonary disease, chronic obstructive 10.3 CHRM3 CRP IL6 TRPV1
42 burning mouth syndrome 10.3 IL6 NGF TAC1 TRPV1
43 intestinal disease 10.3 CRP IL6 TAC1 TRPV1
44 spinal disease 10.3 CRP IL6
45 central nervous system disease 10.3 IER3IP1 IL6 NGF TRPV1
46 nervous system disease 10.3 IER3IP1 IL6 NGF TRPV1
47 glucose metabolism disease 10.3 CRP IER3IP1 IL6 TRPV1
48 acquired metabolic disease 10.3 CRP IER3IP1 IL6 TRPV1
49 urinary system disease 10.2 CRP IL6 KLK3 TRPV1
50 castleman disease 10.2 CRP IL6

Comorbidity relations with Bladder Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Bladder Disease:



Diseases related to Bladder Disease
Sources

Symptoms & Phenotypes for Bladder Disease

About this section

UMLS symptoms related to Bladder Disease:


bladder fullness sensation

MGI Mouse Phenotypes related to Bladder Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 CHRM3 CRP HBEGF IDO1 IL6 MCU
2 homeostasis/metabolism MP:0005376 9.73 CRP HBEGF IDO1 IL6 MCU NGF
3 respiratory system MP:0005388 9.17 CHRM3 HBEGF IL6 MCU P2RX2 P2RX3
Sources

Drugs & Therapeutics for Bladder Disease

About this section

Drugs for Bladder Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 598)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
2 Mirabegron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 223673-61-8 9865528
3
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
4
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5633-20-5 4634
5
Doxazosin Approved Phase 4 74191-85-8 3157
6
Propiverine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60569-19-9 4942
7
Fesoterodine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 286930-03-8, 286930-02-7 6918558
8
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 106133-20-4 129211
9
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
10
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
11
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
13
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 84093 441203 2767
14
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
15
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 85721-33-1 2764
18
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 2 67-20-9 5353830
19
Citalopram Approved Phase 4 59729-33-8 2771
20
Azithromycin Approved Phase 4 83905-01-5 55185 447043
21
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
22
Darifenacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 133099-04-4 444031
23
Silodosin Approved Phase 4 160970-54-7
24
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
25
Cefixime Approved, Investigational Phase 4,Phase 3 79350-37-1 54362 5362065
26
Fosfomycin Approved Phase 4,Not Applicable 23155-02-4 446987
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
28
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
29
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
30
Alfuzosin Approved, Investigational Phase 4,Phase 3 81403-80-7 2092
31
Morphine Approved, Investigational Phase 4 57-27-2 5288826
32
Acetaminophen Approved Phase 4 103-90-2 1983
33
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
34
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
35
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
36
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
37
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
38
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
39
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
40
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
41
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 93-14-1 3516
42
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3 60142-96-3 3446
43
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2,Phase 3 56-12-2 119
44
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
45
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
46
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
47
Cephalexin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 15686-71-2 27447
48
Alverine Approved, Investigational Phase 4 150-59-4 3678
49
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
50
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192

Interventional clinical trials:

(show top 50) (show all 1655)
# Name Status NCT ID Phase Drugs
1 Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract Unknown status NCT02366676 Phase 4 IALURIL
2 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
3 Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Unknown status NCT02540707 Phase 4 solifenacin;mirabegron
4 MIrabegron With oveRACtive bLadder Symptoms in mEn Unknown status NCT02361502 Phase 4 mirabegron;placebo
5 Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity Unknown status NCT02009540 Phase 4 Botulinum toxin injected to bladder body;Botulinum toxin injected into trigone
6 Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients Unknown status NCT01876186 Phase 4 Solifenacin for 12 weeks;Solifenacin for 24 weeks
7 Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Unknown status NCT01423838 Phase 4 Solifenacin;Oxybutynin
8 Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome Unknown status NCT00313924 Phase 4 DETRUSITOL
9 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
10 Comparative Study of Mesh Versus No Mesh in Prolapse Surgery Unknown status NCT00153257 Phase 4
11 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
12 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
13 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
14 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
15 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
16 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
17 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
18 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Completed NCT02297100 Phase 4 Onabotulinumtoxin A
19 Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
20 Ibuprofen Versus Mecillinam for Uncomplicated Cystitis Completed NCT01849926 Phase 4 Ibuprofen;Mecillinam
21 A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department Completed NCT01749605 Phase 4 Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days;ciprofloxacin 250 mg BID x 3 days
22 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
23 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Completed NCT01661621 Phase 4 Detrusitol 4 mg QD;Doxazosin 4 mg QD
24 Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
25 Reproducibility Study of OABSS and Its Response to Treatment Completed NCT02667470 Phase 4 Solifenacin
26 Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. Completed NCT02468375 Phase 4 mirabegron 50mg
27 Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Completed NCT02294396 Phase 4 Mirabegron tablet;Solifenacin tablet;Propiverine tablet;Imidafenacin tablet;Tolterodine capsule
28 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Completed NCT02216214 Phase 4 Mirabegron;Placebo
29 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Completed NCT02138747 Phase 4 Mirabegron;Tolterodine ER
30 The Effect of Anticholinergics on Cognitive Function in the Elderly Completed NCT01922115 Phase 4 Trospium Chloride;Placebo
31 Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome Completed NCT01824420 Phase 4 Detrusitol 4mg QD and Oxybutynin ER 5mg QD;Detrusitol 4mg QD
32 A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients Completed NCT01745094 Phase 4 mirabegron;solifenacin
33 Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder Completed NCT01578304 Phase 4 Imidafenacin;Fesoterodine
34 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) Completed NCT01533597 Phase 4 Solifenacin;Solifenacin plus Tamsulosin
35 A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment Completed NCT01318837 Phase 4 solifenacin
36 Therapy of the Overactive Bladder Syndrome Completed NCT01314781 Phase 4 solifenacin
37 A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine Completed NCT01302067 Phase 4 Fesoterodine 8mg;Fesoterodine 4mg;Placebo
38 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4 Fesoterodine 8 mg;Placebo
39 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial Completed NCT01178827 Phase 4 trospium chloride;oxybutynin IR;oxybutynin IR placebo
40 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. Completed NCT01093534 Phase 4 Placebo;solifenacin
41 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily Completed NCT01089751 Phase 4 trospium chloride;placebo
42 Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder Completed NCT01054222 Phase 4 Fesoterodine;Fesoterodine
43 Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency Completed NCT00979472 Phase 4 Solifenacin
44 Trospium Chloride XR in Obese Female Patients With Overactive Bladder Completed NCT00932022 Phase 4 Trospium Chloride, Extended Release (XR)
45 Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms Completed NCT00928395 Phase 4
46 A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder Completed NCT00928070 Phase 4 Fesoterodine;Placebo
47 A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency Completed NCT00911937 Phase 4 Fesoterodine;Placebo
48 Validation of a Real-time Urodynamic Measure of Urinary Urgency Completed NCT00909428 Phase 4 Solifenacin Succinate
49 Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder Completed NCT00903045 Phase 4 Propiverine hydrochloride;Placebo
50 Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients Completed NCT00902421 Phase 4 Selective serotonin reuptake inhibitors;Antimuscarinics

Search NIH Clinical Center for Bladder Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Disease:
Neo-Urinary Conduit
Embryonic/Adult Cultured Cells Related to Bladder Disease:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder diseases

Sources

Genetic Tests for Bladder Disease

About this section
Sources

Anatomical Context for Bladder Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Disease:

19
The Bladder

MalaCards organs/tissues related to Bladder Disease:

41
Prostate, Testes, Spinal Cord, Kidney, Lung, T Cells, Lymph Node
Sources

Publications for Bladder Disease

About this section

Articles related to Bladder Disease:

(show top 50) (show all 164)
# Title Authors Year
1
Study on the Relation between Colorectal Cancer and Gall Bladder Disease. ( 28511430 )
2017
2
From gene discovery to new biological mechanisms: heparanases and congenital urinary bladder disease. ( 26315301 )
2015
3
Re: The Pharmacological rationale for combining muscarinic receptor antagonists and I^-adrenoceptor agonists in the treatment of airway and bladder disease. ( 25523672 )
2015
4
Prognostic Relevance of Human Telomerase Reverse Transcriptase (hTERT) Expression in Patients with Gall Bladder Disease and Carcinoma. ( 25854384 )
2015
5
The pharmacological rationale for combining muscarinic receptor antagonists and I^-adrenoceptor agonists in the treatment of airway and bladder disease. ( 24682092 )
2014
6
Financial cost to institutions on patients waiting for gall bladder disease surgery. ( 25603667 )
2014
7
Gastric pouch after simple or radical cystectomy for benign and malignant bladder disease. ( 25738108 )
2014
8
Genetics of human congenital urinary bladder disease. ( 23584850 )
2013
9
Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. ( 23013190 )
2012
10
Remodeling of the muscle layer (detrusor muscle) of hyperactive bladder disease in patients with benign prostatic hyperplasia. ( 23113284 )
2012
11
Muscarinic acetylcholine receptor M3 mutation causes urinary bladder disease and a prune-belly-like syndrome. ( 22077972 )
2011
12
The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. ( 22046200 )
2011
13
A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. ( 21855919 )
2011
14
Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. ( 19634167 )
2010
15
Prevalence and characteristics associated with self-reported gall bladder disease in Mexican American elders: results from the Hispanic Established Populations for Epidemiologic Studies in the Elderly (H-EPESE). ( 19225267 )
2009
16
A four-year-old with Streptococcus pneumoniae--associated hemolytic uremic syndrome and gall bladder disease necessitating cholecystectomy. ( 19286616 )
2009
17
Overactive bladder disease: the urge for better therapies. ( 18500915 )
2008
18
TRPs in bladder diseases. ( 17560087 )
2007
19
Higher risk of gall bladder disease in oestrogen users. ( 28055473 )
2005
20
A study of the bacteriological pattern in gall bladder disease. 1986. ( 15485196 )
2004
21
Extracorporeal electromagnetic stimulation for urinary incontinence and bladder disease. ( 15088922 )
2003
22
In vivo optical coherence tomography feasibility for bladder disease. ( 11832776 )
2002
23
Bladder disease: A report based on the smooth muscle function in health and disease satellite meeting to the International Congress of Physiology. ( 12734603 )
2001
24
Electromagnetic pelvic floor stimulation for urinary incontinence and bladder disease. ( 11795645 )
2001
25
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11167643 )
2001
26
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11564042 )
2001
27
EAU - 15th Congress. Urinary incontinence and bladder disease. ( 16080050 )
2000
28
Review article: epidemiology of gall-bladder disease--role of intestinal transit. ( 10902996 )
2000
29
Nitric oxide synthase expression in neurogenic bladder disease: a pilot study. ( 10218094 )
1999
30
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen. ( 9471136 )
1998
31
Gall bladder disease and ABO blood group. ( 10456157 )
1997
32
Long-term follow-up after clam ileocystoplasty. Complications and results including some quality-of-life parameters for 32 patients treated for neuropathic and nonneuropathic bladder disease. ( 8178380 )
1994
33
Alterations to the electrophysiology of isolated human detrusor smooth muscle cells in bladder disease. ( 8309000 )
1994
34
Risk factors for symptomatic gall bladder disease. ( 7959216 )
1994
35
Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study. ( 8307429 )
1994
36
Risk factors for the development of gall bladder disease. ( 18668936 )
1994
37
Is gallbladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 8321495 )
1993
38
Superficial bladder disease: case studies and therapeutic advances. ( 1466118 )
1992
39
Is gall bladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 1465273 )
1992
40
Gall bladder disease as seen in a Harare referral hospital centre. ( 2225019 )
1990
41
Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. ( 2925272 )
1989
42
Gall bladder disease: an analytical report of 250 cases. ( 2634700 )
1989
43
Gall bladder disease in Zimbabwe. ( 3194957 )
1988
44
Parathyroid hormone like bioactivity measured by cytochemical bioassay in a patient with malignant bladder disease. ( 3248932 )
1988
45
Looking for gall bladder disease in the patient's iris. ( 3147081 )
1988
46
Painful bladder disease: clinical and pathoanatomical differences in 115 patients. ( 3625848 )
1987
47
Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid) in painful bladder disease. ( 3567484 )
1987
48
Prospective study of intravesical dimethyl sulphoxide in the treatment of chronic inflammatory bladder disease. ( 3828709 )
1987
49
Urine eosinophil cationic protein in painful bladder disease. ( 3304514 )
1987
50
A critical reappraisal of cystometry in neurogenic bladder diseases. ( 3686758 )
1987
Sources

Variations for Bladder Disease

About this section
Sources

Expression for Bladder Disease

About this section
Search GEO for disease gene expression data for Bladder Disease.
Sources

Pathways for Bladder Disease

About this section

Pathways related to Bladder Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Calcium signaling pathway 37
Show member pathways
 11.19 CHRM3 MCU P2RX2 P2RX3
2
Overview of nanoparticle effects 1
10.23 CRP IL6
Sources

GO Terms for Bladder Disease

About this section

Cellular components related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of nuclear inner membrane GO:0005639 8.62 P2RX2 P2RX3

Biological processes related to Bladder Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 excitatory postsynaptic potential GO:0060079 9.58 P2RX2 P2RX3 TRPV1
2 inflammatory response GO:0006954 9.55 CRP IDO1 IL6 TAC1 TRPV1
3 response to pain GO:0048265 9.52 TAC1 TRPV1
4 response to ATP GO:0033198 9.51 P2RX2 P2RX3
5 positive regulation of calcium-mediated signaling GO:0050850 9.49 P2RX2 P2RX3
6 positive regulation of calcium ion transport into cytosol GO:0010524 9.48 P2RX2 P2RX3
7 response to carbohydrate GO:0009743 9.46 P2RX2 P2RX3
8 positive regulation of acute inflammatory response GO:0002675 9.43 IL6 TAC1
9 peristalsis GO:0030432 9.37 P2RX2 P2RX3
10 negative regulation of lipid storage GO:0010888 9.32 CRP IL6
11 purinergic nucleotide receptor signaling pathway GO:0035590 9.26 P2RX2 P2RX3
12 behavioral response to pain GO:0048266 9.13 P2RX2 P2RX3 TRPV1
13 urinary bladder smooth muscle contraction GO:0014832 8.8 P2RX2 P2RX3 TRPV1

Molecular functions related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellularly ATP-gated cation channel activity GO:0004931 9.16 P2RX2 P2RX3
2 ATP-gated ion channel activity GO:0035381 8.96 P2RX2 P2RX3
3 purinergic nucleotide receptor activity GO:0001614 8.62 P2RX2 P2RX3
Sources

Sources for Bladder Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....